Aduro Biotech starts dosing in Phase Ib combination trial for oncology

Aduro Biotech has started dosing patients in a Phase Ib clinical trial of its drug candidate ADU-S100 (MIW815) in combination with Novartis ’ PDR001 to treat advanced / metastatic solid tumours or lymphomas.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news